Journal Article

Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration

David W. Haas, John A. Bartlett, Janet W. Andersen, Ian Sanne, Grant R. Wilkinson, John Hinkle, Franck Rousseau, Christiana D. Ingram, Audrey Shaw, Michael M. Lederman and Richard B. Kim

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 43, issue 6, pages 783-786
Published in print September 2006 | ISSN: 1058-4838
Published online September 2006 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/507097
Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C→;T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P = .016).

Journal Article.  2304 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.